Epratuzumab
- Generic Name
- Epratuzumab
- Drug Type
- Biotech
- CAS Number
- 205923-57-5
- Unique Ingredient Identifier
- 3062P60MH9
- Background
Epratuzumab is a humanized monoclonal antibody derived from the murine IG2a monoclonal antibody, LL2 (EPB-2). This agent may subsequently be well matched for use in oncology and the treatment of inflammatory autoimmune disorders, such as lupus.
- Indication
Investigated for use/treatment in leukemia (lymphoid), lymphoma (non-hodgkin's), and systemic lupus erythematosus.
Inotuzumab Ozogamicin Approved for Pediatric Relapsed/Refractory B-Cell ALL
• The FDA has approved inotuzumab ozogamicin for pediatric patients aged 1 year and older with relapsed or refractory (R/R) CD22-positive B-cell acute lymphoblastic leukemia (ALL).
• Clinical trials demonstrated that inotuzumab ozogamicin achieved complete remission (CR) in a significant proportion of patients, with high rates of minimal residual disease (MRD) negativity.
• Inotuzumab ozogamicin, a CD22-directed antibody-drug conjugate, offers a targeted treatment option for pediatric R/R B-cell ALL, addressing a critical unmet need.
• Studies suggest that a dose of 1.8 mg/m2 per cycle is effective and tolerable in pediatric patients, with manageable adverse events like thrombocytopenia and neutropenia.
Advances in CAR-T Cell Therapy for Non-Hodgkin Lymphoma
CAR-T cell therapy has emerged as a promising treatment for Non-Hodgkin Lymphoma (NHL), particularly for patients with chemotherapy-resistant forms of the disease. This article reviews the structure, molecular mechanisms, clinical trial results, and challenges of CAR-T cell-based therapies, focusing on their application in NHL.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath